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Lipoprotein abnormalities in hyperlipidemic and normolipidemic men
on hemodialysis with chronic renal failure. Lipids, lipoproteins, apolipo-
proteins (apo) and apo E polymorphism were determined in 101 men
with chronic renal failure (CRF) were were on hemodialysis and 101
healthy controls matched for age and sex. Patients with CRF on
hemodialysis had significantly higher levels of serum triglycerides,
very-low-density lipoprotein (VLDL) cholesterol, intermediate-density
lipoproteins (IDL), and lower levels of low- and high-density lipopro-
teins (LDL and HDL, respectively) than controls. Regarding apolipo-
proteins, serum apo B concentrations were decreased. Apo C-Ill
concentrations in sera and in VLDL and HDL fractions were signifi-
cantly increased in 35 hemodialysis patients compared with 32 controls.
Seventy-eight of the 101 CRF patients had normal serum cholesterol
and triglycerides (<5.2 mmol/liter and <2.3 mmollliter, respectively).
However, this subgroup also showed a significant increase in VLDL-
triglycerides and serum apo B concentration in addition to changes
observed in the group as a whole. Apo B polymorphism in our study
population did not differ from that reported for other European popu-
lations. According to the different apo E phenotypes, lipids and
lipoprotein composition showed no significant differences in controls or
patients. We conclude that accumulation of triglyceride-rich lipopro-
teins in patients with CRF on hemodialysis may thus be at least in part
related to the enrichment of apo C-Ill in VLDL and HDL fractions.
Lipoprotein profile in hemodialysis patients, including those with
normal serum cholesterol and triglyceride levels, is consistent with high
cardiovascular risk.
Patients with chronic renal failure (CRF) on hemodialysis are
at increased risk for accelerated atherosclerosis. Several risk
factors, including lipoprotein disturbances have been incrimi-
nated in the high cardiovascular mortality observed in this
population. Hypertriglyceridemia, usually moderate, is the
most striking abnormality in patients with CRF on hemodialy-
sis, whereas hypercholesterolemia is uncommon [1—6]. High-
density lipoproteins (HDL), whether associated or not with
hypertriglyceridemia, have been reported to be low in hemodi-
alyzed patients 7—1 1). The mild hypertriglyceridemia in CRF
patients on hemodialysis is considered to be due to an increase
in very-low-density lipoproteins (VLDL) and their remnants
[12, 131. In this regard, intermediate-density lipoprotein (IDL)
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abnormalities have seldom been reported and are only found in
short series of patients with CRF who were on hemodialysis
[14—17], However, studies on lipoprotein composition in nor-
molipidemic patients with CRF who are on hemodialysis are
lacking. Recently, some reports have focused on the role of
apolipoproteins (apo) in accelerated atherosclerosis in these
patients [18—22]. Apo C-lI, C-Ill and E, which play an impor-
tant role in the catabolism of triglyceride-rich lipoproteins, have
not been studied extensively in hemodialysis patients [23, 24].
Lipoprotein abnormalities, mainly hypertriglyceridemia, in
CRF patients on hemodialysis are related at least in part to
insulin resistance and also to deficiency in lipoprotein lipase,
hepatic lipase and lecithin:cholesterol acyltransferase activities
[1—3, 25]. Apo E is primarily associated with VLDL and HDL
in human plasma [26]. On the other hand, apo E in IDL plays an
essential role in clearance of the particle through E and B:E
liver receptors, and modulates plasma lipoprotein composition,
since the different isoforms of apo E show different binding
activities and different rates of catabolism [27, 28]. Thus, the
possibility of apo E polymorphism and also apo C-Il and apo
C-Ill influencing impairment in peripheral VLDL catabolism
and removal of triglycerides in dialyzed patients cannot be ruled
out.
The aim of this study was to establish the lipoprotein profile
in a large number of CRF patients on hemodialysis, considering
separately those with and without hyperlipidemia. With the
hypothesis that triglyceride-rich lipoproteins accumulate in
serum of these patients, apo C-Il and apo C-Ill distribution in
lipoprotein fractions and also the different apo E phenotypes
were analyzed.
Methods
Patients
One hundred and one male CRF patients, aged 20 to 80 years
(57.7 14.6, mean SD), who were on hemodialysis therapy
were studied. The etiology of CRF was chronic glomerulone-
phritis in 28 patients, chronic pyelonephritis in 17, polycystic
renal disease in 16, nephroangiosclerosis in 24, Alport's syn-
drome in one, and unknown in 15. Patients had been dialyzed an
average of 49.9 38.8 months (range 6 to 172). The dialysis
schedule was three to four hours three times a week, using a 0.9
to 1.3 m2 surface cuprophane hollow-fiber filter, and acetate or
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Table 1. Lipoprotein profile in controIs and hemodialysis patients
Controls Patients
N=lol N=lOl P
Serum
Cholesterol 5.25 (0.98) 4.12 (1.06) <0.001
Triglycerides 1.27 (0.59) 1.54 (0.79) <0.01
Apo A-I 1.45 (0.37) 1.31 (0.40) NS
Apo B 0.98 (0.22) 0.68 (0.22) <0.001
ApoE 27.6(11.8) 31.3(11.6) NS
VLDL
Cholesterol 0.36 (0.26) 0.48 (0.38) <0.05
Triglycerides 0.62 (0.43) 0.74 (0.54) NS
Proteins 0.11 (0.07) 0.25 (0.17) <0.001
IDL
Cholesterol 0.19 (0.15) 0.27 (0.27) <0.01
Triglycerides 0.15 (0.08) 0.23 (0.22) <0.005
Proteins 0.07 (0.07) 0.08 (0.07) NS
LDL
Cholesterol 3.25 (0.87) 2.28 (0.74) <0.001
Triglycerides 0.20 (0.08) 0.30 (0.18) <0.001
Proteins 0.51 (0.15) 0.41 (0.14) <0.001
HDL
Cholesterol 1.08 (0.28) 0.84 (0.31) <0.001
Triglycerides 0.06 (0.03) 0.09 (0.06) <0.05
Proteins 1.24 (0.17) 0.98 (0.20) <0.001
VLDL-T/HDL-C 0.64 (0.49) 1.08 (1.08) <0.001
Data are presented as means (SD). Lipids are expressed in mmol/liter;
apo A-I, apo B and proteins are expressed in g/liter; apo E is expressed
in mg/liter. T: triglyceride; C: cholesterol.
bicarbonate dialysate containing glucose 2 g/liter. The mean
body mass index (BMI), calculated from the dry weight, was
23.6 3.6. Coronary heart disease, peripheral vascular disease
and/or cerebrovascular disease were recorded in 26 patients.
The patients received a normocaloric diet, poor in saturated and
rich in mono- and polyunsaturated fats, and containing 1 to 1.2
g!kglday of proteins. Patients were also placed on a low water
and potassium intake. Thirty patients with hypertension re-
ceived treatment with angiotensin-converting enzyme inhibitors
or calcium channel blockers. Erythropoietin was given in 19
patients because of hemoglobin levels under 8 g/dl; at the time
of the study, after 6 to 18 months of therapy, hemoglobin levels
were between 9 and 10 g/dl. Patients received no other medi-
cation except multivitamins, calcitriol, phosphate binders, so-
dium polystyrene sulfonate and/or iron. Patients with excessive
alcohol consumption, diabetes mellitus, obesity (BMI  30),
liver disease, systemic illnesses, or other metabolic or endo-
crine disorders were excluded.
One hundred and one healthy men age-matched with the
patients were used as controls, and were recruited from Hos-
pital and University staff, non-retributed blood donors and
subjects who attended the Ophthalmology outpatient clinic for
visual acuity examination. This control group was judged free
of any illness by history, clinical examination and routine
laboratory data. BMI in all cases was <30 (25.3 2.8).
Methods
Blood samples were taken after 12 hours or more of fasting,
immediately before the start of a dialysis session. The VLDL
fraction (d <1.006 glml) was isolated by preparative ultracen-
trifugation [291 in an ultracentrifuge Centrikon T-l055 (Kontron
Instruments, Milan, Italy) using a TVF 50.38 rotor (Kontron
Table 2. Apo C-Il and apo C-Ill concentrations in sera and
lipoproteins in controls and patients
Controls
N=32
Patients
N=35 P
Serum
Apo C-Il 31.8 (8.9) 32.6 (7.2) NS
Apo C-Ill 75.5 (31.2) 133.9 (69.8) <0.001
VLDL
Apo C-lI 4.2 (1.4) 3.5 (1.8) NS
Apo C-Ill 11.9 (11.4) 37.7 (17.8) <0.001
HDL
Apo C-Il 6.7 (3.4) 13.0 (6.6) <0.05
Apo C-Ill 29.3 (13.5) 66.8 (27.3) <0.001
Data are presented as means (sn). Results are expressed in mg/liter.
Instruments). The other lipoproteins (IDL 1.006 < d < 1.019
g/ml, LDL 1.019 < d < 1.063 g/ml and HDL> 1.063 g/ml) were
isolated by density gradient ultracentrifugation [30, 311 in a TST
41.14 rotor. Serum cholesterol and serum triglycerides were
assayed enzymatically [32, 33] as well as cholesterol and
triglycerides of lipoprotein fractions. Proteins of each isolated
fraction were determined by a colorimetric method. Serum apo
A-I and apo B were quantified by immunophelometry with
reagents supplied by Beckman Instruments (Fullerton, Califor-
nia, USA), and serum apo E concentration was determined by
radial immunodiffusion (Daiichi Pure Chemical Co., Tokyo,
Japan). Apo C-Il and apo C-Ill concentrations were determined
by radial immunodiffusion (Daiichi Pure Chemical Co.) in sera
and also in VLDL and HDL fractions in 35 patients and 32
controls. Apo E polymorphism was studied in all 202 subjects
by isoelectric focusing from delipidated VLDL as described
previously by Eto, Watanabe and lschii [34].
Statistical analysis
Comparison between two groups was made using Student's
t-test for independent samples and nonparametric Mann-Whit-
ney test. Lipoprotein values in the different apo E phenotypes
were compared by one-way analysis of variance, and differ-
ences between groups were tested by Tukey test. The correla-
tion between continuous variables was calculated by the Pear-
son correlation test. Contingency tables of apo E phenotypes
were compared by the chi-square test.
Results
Serum triglycerides and lipids carried by VLDL and IDL
were significantly raised in CRF patients on hemodialysis,
whereas serum cholesterol, HDL and apo B levels were de-
creased (Table 1). Only 12 (11.8%) patients had serum triglyc-
erides higher than 2.3 mmollliter, and 15 (14.8%) had serum
cholesterol above 5.2 mmollliter. Other lipid, lipoprotein and
apolipoprotein concentrations together with a VLDL-triglyc-
eride/HDL.-cholestero I ratio in patients and controls are also
shown in Table 1. Apo A-I and apo B concentrations did not
significantly differ between the groups. With regard to apo C-TI
and apo C-Ill distribution, apo C-Ill concentration in sera,
VLDL, and HDL fractions was significantly increased in stud-
ied patients (Table 2).
To assess lipoprotein abnormalities in normolipidemic sub-
jects, a subgroup with cholesterol serum levels lower than 5.2
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Table 3. Lipoprotein profile in controls and patients with serum
cholesterol lower than 5.2 mmol/liter and serum triglycerides below
2.3 mmol/liter
Controls
N=52
Patients
N=78 P
Serum
Cholesterol 4.49 (0.52) 3.75 (0.83) <0.001
Triglycerides 1.00 (0,34) 1.28 (0.47) <0.005
Apo A-I 1.41 (0.38) 1.34 (0.44) NS
Apo B 0.79 (0.15) 0.59 (0.16) <0.001
Apo E 23.8 (11.1) 31.2 (10.2) <0.05
VLDL
Cholesterol 0.25 (0.16) 0.39 (0.29) <0.005
Triglycerides 0.44 (0.26) 0.58 (0.30) <0.05
Proteins 0.08 (0.05) 0.23 (0.17) <0.001
IDL
Cholesterol 0.16 (0.15) 0.24 (0.23) <0.05
Triglycerides 0.13 (0.08) 0.18 (0.12) <0.05
Proteins 0.07 (0.07) 0.07 (0.05) NS
LDL
Cholesterol 2.73 (0.62) 2.10 (0.60) <0.001
Triglycerides 0.18 (0.08) 0.27 (0.14) <0.001
Proteins 0.46 (0.12) 0.39 (0.15) <0.05
HDL
Cholesterol 1.06 (0.24) 0.83 (0.29) <0.001
Triglycerides 0.06 (0.02) 0.08 (0.06) <0.005
Proteins 1.25 (0.18) 1.01 (0.19) <0.001
VLDL-T/HDL-C 0.45 (0.32) 0.81 (0.55) <0.001
Data are presented as means (SD). Lipidsare expressed in mmol/liter,
apo A-I, apo B and proteins are expressed in g/liter; apo B is expressed
in mg/liter. T: triglyceride; C: cholesterol.
mmollliter and triglycerides below 2.3 mmol/liter, composed of
78 hemodialysis patients and 52 controls, was analyzed. Except
for apo A-I, values for all lipid and lipoprotein parameters and
VLDL-triglyceride/HDL-cholesterol ratio differed significantly
between patients and controls (Table 3).
No correlation was observed in CRF patients between lipo-
protein profile and age or dialysis duration. Lipids and lipopro-
teins did not differ significantly with either the dialysate com-
position, or with the presence or absence of hypertension.
Lipids and lipoproteins showed no significant differences
among patients with or without cardiovascular disease (coro-
nary heart disease, peripheral vascular disease and/or cere-
brovascular disease), except for IDL-cholesterol with values of
0.36 0.31 mmol/liter (mean SD) in the former and 0.25
0.25 mmol/liter in the later (P < 0.05), apo A-I of 0.85 0.48
g/liter and 1.36 0.41 g/liter (P c 0.005), respectively.
In patients who received erythropoietin therapy, serum cho-
lesterol was significantly decreased (P < 0.05) compared with
those who did not (3.60 0.82 mmol/liter vs. 4.24 1.06
mmollliter, respectively), as also occurred for LDL-cholesterol
(1.96 0.64 mmoL/liter vs. 2.33 0.75 mmol/liter, respective-
ly).
Apo E phenotypes in CRF patients on hemodialysis were
distributed as follows: E3/E2 in 16.8%, E3/E3 in 60.4%, E4/E2
in 1.9%, E4/E3 in 16.8%, E4/E4 in 1.9% and E2/E2 in 1.9%.
This distribution did not differ from that of controls (E3/E2 in
11.3%, E3/E3 in 70.3%, E4/E2 in 1.9%, E4/E3 in 12.8% and
E4/E4 in 2.9%). According to the different apo E phenotypes,
Table 4. Lipids, lipoproteins, and Apo B phenotypes in hemodialysis
patients
B-4/E-3
N=l7
E-3/E-2
N=l7
E-3/E-3N=6l
Serum
Cholesterol 4.55 (0.79) 4.04 (0.89) 4.05 (1.12)
Triglycerides 1.74 (0.77) 1.44 (0.77) 1.50 (0.81)
Apo A-I 1.30 (0.28) 1.36 (0.57) 1.30 (0.38)
Apo B 0.75 (0.18) 0.63 (0.17) 0.69 (0.23)
Apo B 25.6 (7.2) 31.0 (11.0) 33.3 (12.4)
VLDL
Cholesterol 0.55 (0.39) 0.44 (0.42) 0.48 (0.37)
Triglycerides 0.94 (0.62) 0.68 (0.47) 0.71 (0.55)
Proteins 0.24 (0.11) 0.23 (0.14) 0.27 (0.21)
IDL
Cholesterol 0.39 (0.39) 0.38 (0.38) 0.22 (0.22)
Triglycerides 0.24 (0.18) 0.22 (0.22) 0.23 (0.22)
Proteins 0.08 (0.05) 0.08 (0.05) 0.08 (0.07)
LDL
Cholesterol 2.56 (0.70) 2.17 (0.73) 2.25 (0.71)
Triglycerides 0.24 (0.15) 0.30 (0.22) 0.32 (0.17)
Proteins 0.42 (0.13) 0.41 (0.10) 0.40 (0.16)
HDL
Cholesterol 0.74 (0.22) 0.79 (0.33) 0.87 (0.32)
Triglycerides 0.10 (0.07) 0.08 (0.04) 0.09 (0.05)
Proteins 0.89 (0.17) 1.01 (0.20) 1.00 (0.20)
VLDL-T/HDL-C 1.42 (1.15) 1.11 (1.11) 0.98 (0.98)
Data are presented as means (sri). Lipids are expressed in mmol/liter;
apo A-I, apo B and proteins are expressed in g/liter; apo E is expressed
in mg/liter. T: triglyceride; C: cholesterol.
lipids and lipoprotein composition showed no significant differ-
ences in controls or patients (Table 4).
Discussion
Cardiovascular disease is known to be one of the leading
causes of death in patients with CRF on hemodialysis. Although
many factors undoubtedly contribute to premature atheroscle-
rosis, lipid and lipoprotein disturbances have been suggested as
a major cause, and hyperlipidemia has correlated with in-
creased cardiovascular mortality [35]. Hypertriglyceridemia is
the most common lipid abnormality and occurs in 20 to 70% of
patients with CRF receiving hemodialysis [6]. In the present
study hypertriglyceridemia was moderate, and only 11.8% of
patients had serum triglyceride concentrations above 2.3 mmoL1
liter. The low incidence of hypertriglyceridemia in the present
study may be at least in part related to the selection criteria,
excluding patients with diabetes mellitus and those receiving
therapy known to cause changes in lipid and lipoprotein pro-
files. As is well known in the general population and also in
CRF patients on hemodialysis, hypertriglyceridemia is associ-
ated with a decreased HDL concentration [4, 5, 7—9, 11], as
observed in our study population. Recently, the Cholesterol
Lowering Atherosclerosis Study [36] supported the hypothesis
that at least some VLDL species, such as those enriched by
cholesterol, are atherogenic. In this respect, in the present
study cholesterol carried by VLDL was raised in CRF hyper-
lipidemic and also normolipidemic patients compared with
controls. On the other hand, the finding of an increased VLDL-
protein and protein/lipid ratio in VLDL, in both hyperlipidemic
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and normolipidemic patients, is also consistent with the idea
that VLDL in these patients are atherogenic, since it resembles
that of multiple lipoprotein-type hyperlipidemia, a highly
atherogenic disease [26]. It is noteworthy that VLDL-triglycer-
ide/HDL-cholesterol ratio which reflects triglyceride catabo-
lism [37] was significantly higher in the whole group of dialyzed
patients and even in normotriglyceridemic patients. This finding
suggests impaired metabolism of triglyceride-rich lipoproteins,
probably related to a decrease in hepatic triglyceride lipase
activity and lipoprotein lipase activity previously reported in
these patients [2, 3]. These abnormalities probably enhanced
the IDL enrichment in cholesterol and triglycerides observed in
the present study, and is in agreement with previous studies
[12—17]. These IDL changes, like other abnormalities in IDL
composition which occur in familial dysbetalipoproteinemia
[38], diabetes mellitus [39], coronary heart disease [40—43], and
peripheral vascular disease [44, 45] may contribute to the
development of atherosclerosis in hyperlipidemic and even
normolipidemic patients on hemodialysis, as is suggested by the
fact that CRF patients with cardiovascular disease had higher
levels of IDL-cholesterol.
Because the hyperlipidemia of patients with CRF on hemo-
dialysis is essentially limited to the triglyceride-rich lipoproteins
our findings on apo C-Il and apo C-Ill distribution in lipoprotein
fractions should provide a better understanding of the role of
these apolipoproteins in these patients. Unlike other investiga-
tors [23, 24], we found no differences in apo C-Il distribution
between patients and controls, except for that contained in
HDL. However, with regard to apo C-Ill, and in agreement
with others [23, 24], our patients showed markedly increased
concentrations in sera, in VLDL and HDL fractions. This
finding may account for the decreased lipoprotein lipase activity
[15, 46, 47], and impaired hepatic uptake of triglyceride-rich
lipoproteins [48—50]. Our findings suggest that apo C-Ill plays a
key role in the altered triglyceride metabolism of hemodialysis
patients. This metabolic dysfunction appears to be responsible
for hypertriglyceridemia in CRF patients on hemodialysis and
may be one of the major risk factors for the accelerated
atherosclerosis in these patients.
In agreement with previous reports, we have observed that
hemodialysis patients display decreased serum apo B concen-
tration [19, 20, 22]. Apo B-LDL is also decreased in hemodial-
ysis patients, and this finding is consistent with a decrease in the
number of LDL particles, since each LDL particle contains
only one apo B molecule [26]. On the other hand, according to
the metabolic pathway proposed by Gregg et a! [281, the
derangement of triglyceride-rich lipoprotein catabolism proba-
bly enhances enrichment in triglycerides by LDL. The signifi-
cantly decreased apo A-I concentration in patients on hemodi-
alysis with cardiovascular disease compared with those without
cardiovascular disease concurs with the idea that apo A-I is the
most useful marker of coronary heart disease [51].
In the present study, lipids and lipoprotein composition do
not appear to be influenced by age, length of time on dialysis,
dialysate composition, the presence or not of hypertension or
the etiology of renal disease. Only in the subset of patients
treated with erythropoietin were serum cholesterol and LDL-
cholesterol decreased. In this respect, prospective and con-
trolled trials are required to ascertain whether lipoprotein
composition is influenced by erythropoietin therapy.
The prevalence of apo E phenotypes in our patients with CRF
did not differ significantly from that of the control group, and
was similar to that previously reported in other European
populations [28, 45, 52—54]. Concerning lipoprotein composi-
tion, no significant differences were observed in relation to apo
E polymorphism. However, in agreement with published data
in subjects other than CRF patients [28, 45, 52—54], serum
cholesterol, LDL-cholesterol and VLDL-triglyceride/HDL-
cholesterol ratio tended to be higher in CRF patients with allele
e4.
In conclusion, patients with CRF on hemodialysis have
deranged triglyceride-rich lipoprotein metabolism with an accu-
mulation of VLDL and IDL, together with a decrease in HDL
and LDL. Abnormalities in the composition of triglyceride-rich
lipoproteins are characterized by the presence of atherogenic
species of VLDL and accumulation of IDL in serum. Although
it is well known that apo E polymorphism modulates IDL and
LDL metabolism, it does not appear to influence substantially
the composition of lipoproteins in the study population. Thus,
accumulation of triglyceride-rich lipoproteins in hemodialysis
patients may be related at least in part to the enrichment of apo
C-Ill in VLDL fraction. Finally, it is noteworthy that in a large
subgroup of patients with normal serum cholesterol and triglyc-
eride levels, lipoprotein composition abnormalities persist.
Thus, despite the existence of other cardiovascular risk factors,
the lipoprotein profile in 'normolipidemic" patients with CRF
on hemodialysis is consistent with high cardiovascular risk.
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